Original Article

Investigation of impact of storage conditions on Hypericum perforatum L. dried total extract

Halil Koyu, Mehmet Zeki Haznedaroglu*

Department of Pharmaceutical Botany, Faculty of Pharmacy, Ege University, Bornova, Izmir 35100, Turkey

ARTICLE INFO

Article history:
Received 25 April 2014
Received in revised form
13 October 2014
Accepted 10 April 2015
Available online 20 May 2015

Keywords:
flavonoids
HPLC analysis
Hypericum perforatum
hypericin
stability

ABSTRACT

Hypericum perforatum L. (Hypericaceae) has been widely prescribed for mild to moderate depression following the release of promising results in clinical trials. However, it is known that its constituents may be affected by milieu. The stability complexities of the constituents of H. perforatum have gained interest in recent years. The aim of the present study was to examine the impact of storage conditions on H. perforatum total extract simultaneously under different storage conditions. Temperature, humidity, and light conditions were evaluated. Comparative analyses of methanol extracts were conducted using high performance liquid chromatography-diode array detection for chlorogenic acid, rutin, hyperoside, isoquercitrin, quercitrin, quercetin, amentoflavone, pseudohypericin, hyperforin, and hypericin. Analysis and extraction were performed using a validated method. The fluctuation of the constituents of the plant extract has been demonstrated. Among these components, chlorogenic acid was the most stable. Hyperforin, hypericin, and pseudohypericin were more stable than the flavonoids at 20°C, in the 6th month. As estimated, decay was lowest at 20°C and highest at 40°C and 75% relative humidity for the analyzed constituents. Except for hyperforin, light protection decreased the breakdown of components within 4 months. However, at the 6th month, equivalent changes were seen for all constituents. Degradation of the constituents at 20°C indicates the importance of stability tests in analysis studies covering time and storage conditions.

1. Introduction

Plants and their preparations have been used by humans in the treatment of various conditions for thousands of years. Use of traditional medicine including medicinal plants remains widespread in developing countries, whereas complementary and alternative medicine use continue to thrive in developed countries [1]. Investigations support complementary and alternative medicine for physical and psychiatric disorders [2]. Thus, medicinal plants are still being widely studied in contemporary pharmaceutical sciences.

Hypericum perforatum L. (HP) has been used for centuries. Its efficacy and indications of use have been well documented by...
numerous scientists beginning with Hippocrates (400 B.C.), followed by Paracelsus [3], and today it is compiled in various pharmacopeias such as European Pharmacopeia, European Scientific Cooperative on Phytotherapy (ESCO P) European Medicines Agency, and World Health Organization Monographs. Commonly, HP has been indicated internally as an antidepressant and used as a wound healer agent externally. Popular products based on this plant, which are used for the treatment of mild and moderate depression, account for a substantial market share in the United States; additionally, it has been prescribed more often than fluoxetine HCl in Germany [4]. HP is a plant tested in numerous clinical trials [5], providing a high level of evidence results [6], whereas it is classified as the most commonly used species in ethnobotanical surveys [7]. In the search for new compounds, quantification of constituents, extract optimization, and standardization of Hypericum species is an important topic [8–11].

Stability tests have been an important part of the testing program for both drug substances and herbal preparations. Recently, investigations on the stability of commonly used herbal extracts have drawn increasing attention [12–15]. Stability is an important issue for HP, which has complex ingredients: hypericin, pseudohypericin (naphthodianthrones); hyperforin (phloroglucinol); hyperoside, quercitrin, quercetin, rutin (flavonoids); and chlorogenic acid (phenolic acids) [16]. Previous reports have demonstrated some problems in relation to the stability of HP extracts. In a study, interdays stability and effects of filtration on major constituents of methanol extract were determined [17]. In another study, hyperforin stability was studied on the lipophilic fraction of extract analyzed using high-performance liquid chromatography (HPLC) [18]. The stability of HP oils prepared with different methods was analyzed using the HPLC-diode array detection (DAD)–MS system [13]. Flavonoids, naphthodianthrones, and phloroglucinol derivatives were evaluated in tincture with HPLC-DAD–MS for accelerated and long-term testing [12]. The stability of hyperforin in maceration of HP dried flowers was also determined using the HPLC system [19]. The thermal and photostability of commercial dried extract was investigated according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) testing conditions [16]. Marketed formulations were analyzed for their hypericin and pseudohypericin content concerning temperature and humidity [20]. The relation between physical and chemical characteristics was likewise examined for HP products [21]. The stability of hypericin and pseudohypericin in extracts of Hyperici herba and standard solutions were studied under different temperatures and light conditions; the results were monitored with visible spectroscopy and HPLC-VIS/DAD [22]. In another study, the content uniformity of the plant and batch-to-batch reproducibility in HP products were investigated [23]. All these studies have important contributions to what we know about extract stability. However, the stability of dried total extract still has complexity and requires further clarification in terms of gathering conditions in one investigation concerning storage parameters such as light, humidity, and temperature together in parallel control. Therefore, the studied parameters were chosen to simulate the conditions usually encountered such as the effects of light, preservation capability of cold storage, and the effects of heat and humidity at rough levels to observe the degradation according to ICH guidelines. To the best of our knowledge, this is the first investigation to cover all the major constituents regarding the impact of storage conditions on H. perforatum dried total extract, including such parameters as humidity, light, and temperature for 6 months in the same context.

In this study, our aim was to determine the impact of storage conditions—such as temperature, humidity, and light conditions—on the constituents of Hypericum perforatum methanolic extract (HPME). Analyses were carried out using the HPLC-DAD system for these components.

2. Methods

2.1. General

HPLC-grade water was obtained with Millipore Type I Ultrapure Water Systems (Millipore, Billerica, MA, USA). HPLC-grade acetic acid was purchased from J.T. Baker (Center Valley, PA, USA); HPLC-grade acetonitrile and methanol were purchased from Labscan (Gliwice, Poland). HPLC standards as hypericin and pseudohypericin were obtained from Planta Natural Products (Vienna, Austria). Rutin, quercitrin, quercetin, and amentoflavone standards were kindly sent by Professor Hasan Kirmizibekmez (Yeditepe University, Istanbul, Turkey); hyperoside and isoquercitrin standards were kindly given by Professor Emrah Kilinc (Ege University, Izmir, Turkey), and hyperforin standard was kindly supplied by Professor Athanassios Giannis (Leipzig University, Leipzig, Germany).

2.2. Plant material

The plant material, collected from a single population of cultivated plants, was kindly provided by the Faculty of Agriculture, Ege University. The plant was identified at the Department of Pharmaceutical Botany, Faculty of Pharmacy, Ege University, and specimen vouchers are kept at the IZEF Herbarium, (Ege University Faculty of Pharmacy International Herbarium) (No. 5796).

2.3. Extraction method

Air-dried aerial parts of the plant (200 mg) were homogenized using a blender and were extracted with 10 mL of methanol by sonication at 11–13 °C for 30 minutes and at 21–23 °C for 30 minutes with exclusion of light. The samples were centrifuged at 7000 g for 10 minutes. The supernatant was separated, and the same procedure was repeated three more times for the precipitate according to Li and Fitzloff’s [17] extraction method. Dry total extract was obtained via evaporation of total solvent using a vacuum evaporator. Total dryness of the extract was achieved using a vacuum concentrator system (yield: 26.5%, w/w).

2.4. Validation of extraction

Validation tests of blank extraction (an extraction procedure done without plant material), spiked blank extraction (blank
extraction with addition of quercetin standard without plant material), reproducibility, repeatability, consistency, and homogeneity (homogeneity of dry extracts in sample tubes from five different points of the tubes) were performed. The recovery test was performed with Morin standard, which could be identified with the same analysis method.

### 2.5. Storage conditions

Storage conditions were determined as follows: room condition (climatized condition at 25°C with uncontrolled humidity) with daylight (case 1) and room condition without daylight, dark (case 2); 25°C–65% relative humidity (RH; case 3) and 40°C–75% RH (case 4); and –20°C (case 5) and 4°C (case 6; Table 1). For all conditions, three sets of dry extract samples in glass vials were located and analyzed by HPLC (n = 3) by preparing fresh samples in each period. The effects of light, temperature, and humidity were studied monthly for 6 months according to the ICH Guidelines [24]. The impact of storage conditions was compared within light conditions, cold storage environment, and ICH guidelines criteria.

### 2.6. Analysis method

Analyses were performed using the method described by Brolis et al [25], with minor modifications. Analyses were conducted using an Agilent 1100 HPLC system equipped with degasser, autosampler, column oven, gradient pump, and PDA detector (Agilent Technologies, Waldbronn, Germany). A column with 4.6 mm diameter, 250 mm length, and 5 µm C18 particle size (ACE-121-2546) is used with 1 cm guard column SC18 (Hi-5C18-10C). The injection volume was 20 µL, and the flow rate was 1 mL/min. The column oven was set at 30°C; the wavelength was set at 270 nm and 590 nm. The gradient system of the mobile phase is given in Table 2.

The calibration was studied with seven concentration points of five injections for chlorogenic acid (1.25–80 µg/mL), rutin (1–64 µg/mL), hyperoside (2.5–160 µg/mL), isoquercitrin (1.25–80 µg/mL), quercitin (0.5–32 µg/mL), quercetin (0.25–16 µg/mL), amentoflavone (0.125–8 µg/mL), pseudohypericin (0.25–16 µg/mL), hypericin (0.25–16 µg/mL), and hyperforin (2.5–160 µg/mL) with regression (r²) of > 0.9994.

### 3. Results and discussion

*H. perforatum* L. has been widely prescribed following the release of promising results in clinical trials [4]. Consequently, the stability complexity of HP compounds has attracted great interest. In this study, HPME constituents were evaluated for the interpretation of stability considering different storage conditions including the effect of light, cold storage conditions, and ICH guidelines criteria.

Validation tests on extraction and analysis were performed. Tests of blank and quercetin spiked blank extraction continued with recovery test. Morin as an external compound similar to analyzed constituents was used for recovery tests, achieving 90% recovery. Extraction repeatability tests gave the following relative standard deviation (RSD) values: chlorogenic acid, 2.1%; rutin, 4.6%; hyperoside, 2.3%; isoquercitrin, 3.8%; quercitin, 7.8%; quercetin, 14%; amentoflavone, 17.8%; pseudohypericin, 16%; hyperforin, 3.4%; and hypericin, 15.3%. The homogeneity of the dry extract was also tested; considering the part taken from the sample tube that was analyzed could affect the results. Samples from five different points of a dry extract in a test tube were analyzed, and results showed that hyperforin had 10.6% RSD and hypericin had 11.0% RSD, whereas the maximum RSD was observed for quercetin at 16.8%. To clarify if any components were left after the extraction procedure, extraction of disposed precipitates was performed. Hyperforin and hypericin were not detected; only rutin, hyperoside, and isoquercitrin (with maximum 8.6%) were calculated.

HPME was examined for phloroglucinols (hyperforin), naphtodianthrones (hypericin, pseudohypericin), flavonoids (rutin, hyperoside, isoquercitrin, quercitrin, quercetin, and amentoflavone), and quinic acid derivative (chlorogenic acid). The analysis was performed using HPLC-DAD (n = 9) every month for a period of 6 months. Validation of the analysis conditions—electric repeatability (maximum for hypericin 0.06% RSD), stability of reference standards in a day (maximum for hyperforin 1.7% RSD) and interdays (maximum for hypericin 21% RSD)—was performed. The chromatogram and RT values are given in Figs. 1 and 2. All 10 compounds were in the same exact order as in the other studies with aspect of retention time (RT) (Figs. 1 and 2) [13,17,25]. The analyzed amounts of the components are in accordance with the literature data [13,17,25]. Only the amounts of hypericins and hyperforin were observed to have increased as the studied plant material was collected from a cultivated plant population of a composition enrichment study.

Results of the analysis for 6 months are summarized in Tables 3–5, within corresponding cases.

Mainly hypericin has been indicated as the marker compound of the plant to be standardized with in pharmacopeias, monographs, and related literature [3,5]. However, recent studies have shown that all constituents might directly or indirectly contribute to bioactivity [12,16,20,21]. Considering this controversy, all constituents in the total extract were regarded within commonly encountered conditions in our study.

Storage conditions were determined as follows: room condition with daylight (case 1) and room condition without

| Table 1 – Storage conditions. |
|---|---|---|
| **Case** | **Condition** | **Aim of investigation** |
| 1 | 25°C–daylight | Effect of light |
| 2 | 25°C–dark | Effect of temperature and humidity |
| 3 | 25°C–65% RH | Effect of light |
| 4 | 40°C–75% RH | Effect of cold storage |
| 5 | –20°C | Effect of cold storage |
| 6 | 4°C | Effect of cold storage |

RH = relative humidity.

| Table 2 – Gradient analysis system. |
|---|---|---|---|---|---|---|---|---|
| **Mobile phase** (minute) | 0 | 10 | 30 | 40 | 55 | 56 | 65 |
| 99.7% water–0.3% acetic acid | 100 | 85 | 70 | 10 | 5 | 100 |
| Acetonitrile | 0 | 15 | 20 | 75 | 80 | 0 | 0 |
| Methanol | 0 | 0 | 10 | 15 | 0 | 0 | 0 |


daylight, dark (case 2); 25°C–65% RH (case 3) and 40°C–75% RH (case 4). – 20°C (case 5) and 4°C (case 6). The conditions were chosen to investigate the effects of temperature, humidity, and light. The effect of light on HPME was observed in case 1 and case 2. Cases 3 and 4 were set up to investigate the percentage of degradation, based on ICH guidelines [24]. Climate cabins were used to show the effect of heat and humidity on the percentage of degradation under extreme conditions. The potential protective effect of cold (low) temperatures on the stability of components was examined at –20°C and 4°C. The results are compiled within relevant cases.

Under light and dark room conditions, all compounds except chlorogenic acid degraded by >24% within 4 months (results are presented in Table 3). At the end of the 4th month, keeping the extract in the dark at room condition led to a significant improvement in the stability of pseudohypericin, but not for hypericin and hyperforin. Flavonoids, except hyperoside, were highly durable for 4 months in the dark at room condition, but lost their stability at the 6th month in both dark and light conditions. The dark condition provided improved stability when compared to light for 4 months. At the 6th month, the degradative effect of time overwhelmed the protective effect of dark on the stability of flavonoids.

Under the 25°C–65% RH and 40°C–75% RH conditions, flavonoids and chlorogenic acid degraded more than hypericin and hyperforin did between the 4th month and 6th month (Table 4). Therefore, the discussion of our study mainly focused on the values of the 4th month and 6th month. At 25°C–65% RH, the degradation percentages were similar to those at room condition with or without daylight. The extreme condition of 40°C–75% RH gave the highest degradation values. Pseudohypericin, hypericin, and hyperforin were the compounds that degraded the most in 40°C–75% RH, reaching values of 65%, 85%, and 69%, respectively, at the end of the 6th month. Increase in humidity and temperature enhanced the degradation.

The breakdown of pseudohypericin and hypericin was close at the end of the 4th month for both –20°C and 4°C as presented in Table 5. By contrast, at the 6th month, differentiation in –20°C resembled that in 25°C–65% RH. At the 4th month for –20°C, 4°C, and dark room conditions, similar results were observed for pseudohypericin and hyperoside—showing that cold conditions could not provide significant protective effects for 4 months. Flavonoids (except hyperoside) were more stable at –20°C compared to 4°C for 4 months; however, at the end of the 6th month the degradation
### Table 3 – Degradation percentages of constituents at room conditions of daylight and darkness during 6 months of stability trial (n = 3).

| Constituent | Degradation % | Standard Deviation |
|-------------|----------------|-------------------|
| Chlorogenic acid | 5.0 ± 0.14 | 5.1 ± 0.5 (3.0) |
| Rutin        | 20.7 ± 0.02 | 20.2 ± 1.6 (2.2) |
| Hyperoside   | 38.8 ± 0.06 | 33.0 ± 0.9 (14.9) |
| Quercetin    | 9.9 ± 0.04 | 9.5 ± 0.8 (8.7) |
| Quercetin    | 3.2 ± 0.02 | 3.0 ± 0.2 (6.2) |
| Amentoflavone| 6.0 ± 0.08 | 5.6 ± 0.5 (6.2) |
| Pseudohypericin| 8.5 ± 0.08 | 7.6 ± 1.7 (10.2) |
| Hyperinin    | 2.9 ± 0.02 | 2.2 ± 0.2 (22.9) |
| Hyperforin   | 69.8 ± 0.38 | 54.0 ± 2.3 (22.6) |

### Table 4 – Degradation percentages of constituents in 25 °C - 65% RH and 40 °C - 75% RH conditions during 6 months of stability trial (n = 3).

| Constituent | Degradation % | Standard Deviation |
|-------------|----------------|-------------------|
| Chlorogenic acid | 5.0 ± 0.14 | 5.1 ± 0.5 (2.2) |
| Rutin        | 20.7 ± 0.02 | 20.2 ± 1.6 (2.2) |
| Hyperoside   | 38.8 ± 0.06 | 33.0 ± 0.9 (14.9) |
| Quercetin    | 9.9 ± 0.04 | 9.5 ± 0.8 (8.7) |
| Quercetin    | 3.2 ± 0.02 | 3.0 ± 0.2 (6.2) |
| Amentoflavone| 6.0 ± 0.08 | 5.6 ± 0.5 (6.2) |
| Pseudohypericin| 8.5 ± 0.08 | 7.6 ± 1.7 (10.2) |
| Hyperinin    | 2.9 ± 0.02 | 2.2 ± 0.2 (22.9) |
| Hyperforin   | 69.8 ± 0.38 | 54.0 ± 2.3 (22.6) |

t₀ = starting point; Deg % = Degradation percentage; ± = standard deviation.
Degradation percentages of constituents in −20 °C and 4 °C conditions during 6 months of stability trial (n = 3).

| Constituent   | mg/g (Deg %) 1st month | mg/g (Deg %) 2nd month | mg/g (Deg %) 3rd month | mg/g (Deg %) 4th month | mg/g (Deg %) 5th month | mg/g (Deg %) 6th month |
|--------------|-------------------------|-------------------------|-------------------------|------------------------|------------------------|------------------------|
| Chlorogenic acid | 5.0 ± 0.14 (−8.7%) | 6.0 ± 0.8 (−20.7) | 7.0 ± 0.4 (−32.8) | 8.0 ± 0.6 (−45.2) | 9.0 ± 0.8 (−57.3) | 10.0 ± 1.0 (−69.4) |
| Rutin        | 20.7 ± 0.02 (40.3) | 206.4 ± 0.4 (80.9) | 204.4 ± 1.1 (89.9) | 202.4 ± 1.5 (99.4) | 200.4 ± 1.9 (99.9) | 198.4 ± 2.3 (90.3) |
| Hyperoside   | 38.8 ± 0.06 (73.2) | 340.7 ± 0.1 (73.3) | 320.7 ± 0.6 (75.7) | 277.5 ± 0.5 (78.5) | 235.5 ± 0.9 (79.9) | 193.5 ± 1.2 (77.3) |
| Isoquercetin | 29.5 ± 0.82 (41.2) | 193.4 ± 0.2 (41.4) | 190.1 ± 0.2 (41.4) | 182.3 ± 0.3 (41.4) | 176.9 ± 0.4 (41.4) | 172.9 ± 0.5 (41.4) |
| Quercetin    | 9.9 ± 0.82 (11.4) | 104.4 ± 0.2 (11.4) | 104.7 ± 0.9 (11.4) | 107.4 ± 1.1 (11.4) | 109.2 ± 1.4 (11.4) | 111.5 ± 1.7 (11.4) |
| Quercetin    | 1.2 ± 0.02 (2.7) | 3.2 ± 0.06 (2.7) | 3.1 ± 0.09 (2.7) | 2.9 ± 0.19 (2.7) | 2.4 ± 0.32 (2.7) | 1.9 ± 0.45 (2.7) |
| Amentoflavone | 6.0 ± 0.08 (12.0) | 59.0 ± 0.1 (12.0) | 59.0 ± 0.2 (12.0) | 58.0 ± 0.3 (12.0) | 57.0 ± 0.4 (12.0) | 54.0 ± 0.5 (12.0) |
| Pseudo-hyperforin | 8.5 ± 0.82 (11.4) | 82.4 ± 0.2 (11.4) | 80.0 ± 0.2 (11.4) | 78.0 ± 0.3 (11.4) | 75.0 ± 0.4 (11.4) | 73.0 ± 0.5 (11.4) |
| Hyperforin   | 2.9 ± 0.02 (5.7) | 28.0 ± 0.3 (5.7) | 27.0 ± 0.5 (5.7) | 25.0 ± 0.7 (5.7) | 23.0 ± 0.9 (5.7) | 21.0 ± 1.1 (5.7) |
| Hyperforin   | 60.8 ± 0.38 (12.0) | 88.0 ± 0.25 (12.0) | 94.0 ± 0.6 (12.0) | 90.0 ± 0.8 (12.0) | 87.0 ± 1.0 (12.0) | 83.0 ± 1.2 (12.0) |

b₀ = starting point; Deg % = degradation percentage; ± = standard deviation.

4. Conclusion

The instability of the individual active constituents of H. perforatum, as well as the overall extract, is due to the instability of the constituents in the extract and the compounds of the extract degrade at different rates. The results indicate that the instability of the extract is due to the sum of the individual constituent instabilities. Therefore, the presence of a single instability constituent can lead to the instability of the extract. The degradation of the extract is also dependent on the environmental conditions, such as temperature and humidity. To understand the degradation of the extract, it is necessary to investigate the degradation rates of the individual constituents and the overall extract. The instability of the extract is due to the instability of the individual constituents, and the overall extract is due to the sum of the individual constituent instabilities. Therefore, to understand the stability of the extract, it is necessary to investigate the degradation rates of the individual constituents and the overall extract.
in addition, unpredictable interactions and side effects could also occur.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgments

The authors are thankful to the Research and Application Center of Drug Development and Pharmacokinetics (ARGE-FAR) and Prof. Dr. Ulvi Zeybek for facilities; Prof. Hasan Kirimizibekmez, Prof. Emrah Kilinc, Prof. Athanassios Giannis and Planta Natural Products for HPLC standards. This study was supported by Ege University Project Fund 08/ECZ/005.

REFERENCES

[1] World Health Organization. WHO traditional medicine strategy 2002–2005. 2002/11/28 ed. Geneva. 2002 May–Jun.
[2] van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry 2008;21:37–42.
[3] Blumenthal M, Brinckmann J, Wollschaeger B. The ABC clinical guide to herbs. 1st ed. Austin, TX: American Botanical Council; 2003. p. 321–34.
[4] Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002;9:1–33.
[5] European Scientific Cooperative on Phytotherapy. E/S/C/O/P monographs : the scientific foundation for herbal medicinal products. 2nd ed. Exeter: Thieme; 2003.
[6] Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol 2011;21:841–60.
[7] Polat R, Satil F. An ethnobotanical survey of medicinal plants in Edremit Gulf (Balikesir-Turkey). J Ethnopharmacol 2012;139:626–41.
[8] Bagdonaite E, Martonfi P, Repcak M, Labokas J. Variation in concentrations of major bioactive compounds in Hypericum perforatum L. from Lithuania. Ind Crop Prod 2012;35:302–8.
[9] Bertoli A, Cirak C, Leonardi M, Seyis F, pistelli L. Morphogenetic changes in essential oil composition of Hypericum perforatum during the course of ontogenesis. Pharm Biol 2011;49:741–51.
[10] Cirak C, Bertoli A, pistelli L, Seyis F. Essential oil composition and variability of Hypericum perforatum from wild populations of northern Turkey. Pharm Biol 2011;48:906–14.
[11] Bonkanka CX, Sanchez-Mateo Cdel C, Rabanal RM. Antinociceptive activity of Hypericum grandifolium Choisy in mice. J Nat Med 2011;65:122–8.
[12] Bilia AR, Bergonzi MC, Mazzi G, Vincieri FF. Analysis and stability of the constituents of artichoke and St. John’s wort tinctures by HPLC-DAD and HPLC-MS. Drug Dev Ind Pharm 2002;28:609–19.
[13] Isacchi B, Bergonzi MC, Carnevali F, van der Esch SA, Vincieri FF, Bilia AR. Analysis and stability of the constituents of St. John’s wort oils prepared with different methods. J Pharm Biomed Anal 2007;45:756–61.
[14] Panichayupakaranant P, Itsuruya A, Sirikititham A. Preparation method and stability of eucalyptus acid-rich pomegranate fruit peel extract. Pharm Biol 2010;48:201–5.
[15] Young HY, Chiang CT, Huang YL, Pan FP, Chen GL. Analytical and stability studies of ginger preparations. J Food Drug Anal 2002;10:149–53.
[16] Bilia AR, Bergonzi MC, Morgenni F, Mazzi G, Vincieri FF. Evaluation of chemical stability of St. John’s wort commercial extract and some preparations. Int J Pharmaceut 2001;213:199–208.
[17] Li WK, Fitzloff JP. High performance liquid chromatographic analysis of St. John’s Wort with photodiode array detection. J Chromatogr B 2001;765:99–105.
[18] Fuzzati N, Gabetta B, Strepponi I, Villa F. High-performance liquid chromatography-electrospray ionization mass spectrometry and multiple mass spectrometry studies of hyperforin degradation products. J Chromatogr A 2001;926:187–98.
[19] Maisenbacher P, Kovar KA. Analysis and stability of Hypericum perforatum. Planta Med 1992;58:351–4.
[20] Shah AK, Avery BA, Wyant CM. Content analysis and stability evaluation of selected commercial preparations of St. John’s wort. Drug Dev Ind Pharm 2005;31:907–16.
[21] Kopleman SH, NguyenPho A, Zito WS, Muller FX, Augsburger LL. Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance. AAPS Pharm Sci 2001;3:E26.
[22] Wirz A, Meier B, Sticher O. Stability of hypericin and pseudohypericin in extract solutions of Hypericum perforatum and in standard solutions. Pharm Ind 2001;63:410–5.
[23] Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilovecz M. Batch-to-batch reproducibility of St. John’s Wort preparations. Pharmacoepidemiol 2001;34:152–6.
[24] European Medicines Agency. ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products, Note for guidance on stability testing: stability testing of new drug substances and products (cpmp/ich/2736/99). London. 2006.
[25] Brolis M, Gabetta B, Fuzzati N, Pace R, Panzeri F, Peterlongo F. Identification by high-performance liquid chromatography diode array detection mass spectrometry and quantification by high-performance liquid chromatography UV absorbance detection of active constituents of Hypericum perforatum. J Chromatogr A 1998;825:9–16.